- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04320511
Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2
December 14, 2021 updated by: Girish B. Nair, MD, William Beaumont Hospitals
COVID CT, Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2
The goal of this study is to evaluate if CT (Computerized Tomography) can effectively and accurately predict disease progression in patients with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).
You may be eligible if you have been diagnosed with SARS-CoV-2, are an inpatient at Beaumont Hospital-Royal Oak and meet eligibility criteria.
After consent and determination of eligibility, enrolled patients will have a CT scanning session.
After the CT scan, patients are followed for 30 days by reviewing their medical records and by phone after discharge from hospital.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Beaumont Quantitative CT lung function imaging (BQLFI) uses mathematical modeling to determine regional differences in ventilation (CT-V) and pulmonary blood mass (PBM) from a pair of inspiration-expiration CT scans or time-resolved four-dimensional (4D) CT scans.
CT-V and PBM images provide surrogates for pulmonary ventilation and perfusion, respectively, in the form of detailed functional maps.
CT-V and PBM therefore allow us to distinguish healthy from abnormal lung.
Moreover, the technique generalizes to recover lung compliance imaging (LCI) when the CT is acquired at different pressure settings, in order to characterize lung stiffness.
PBM and CT-V can detect parenchymal lung function changes at a voxel level and can be used to 1) assess disease progression in SARS-CoV-2, 2) detect treatment effects, and 3) identify early changes in high-risk patients prior to their development of disease.
BQLFI affords the opportunity to provide imaging biomarkers that enable the early diagnosis of lung injury, which in turn cause impairment in gas exchange at the level of alveolar capillary interface.
Currently, there are no available imaging biomarkers to predict patients at risk of progression or identify those at risk of developing severe disease with SARS-CoV-2.
Our proposed study will validate a novel methodology, based on state-of-the-art CT-V and PBM imaging that can accurately measure regional ventilation and perfusion, as a means for improving surveillance, diagnosis, and prognostication of patients with SARS-CoV-2.
This is a prospective, pilot study of 25 adult patients with SARS-CoV-2, who have mild to moderate disease, defined as positive PCR screen and not requiring invasive mechanical ventilator support or noninvasive ventilation or high flow nasal cannula.
Participants will provide informed consent and eligibility will be confirmed.
Demographics and medical history will be obtained.
Participants will undergo one inspiration-expiration CT.
Outcomes and adverse events will be assessed over 30 day using chart review or phone interview.
Study Type
Observational
Enrollment (Actual)
15
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Royal Oak, Michigan, United States, 48073
- Beaumont Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
SARS-COV 2 positive patients who present to Beaumont-Royal Oak Emergency Center
Description
Inclusion criteria:
- Adults >18 years of age
- Written Informed consent
- A confirmed diagnosis of SARS-CoV-2 with mild to moderate disease, on room air or supplemental oxygen not more than 12L
- Concomitant medications for the treatment are allowed
Exclusion criteria:
- Patients <18 years
- Pregnant females
- Invasive ventilator support or non-invasive ventilator support including high flow nasal cannula
- COPD or Congestive Heart Failure patients requiring home oxygen
- History of lung cancer and radiation to lung or had prior radiation to the chest
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with SARS-COV 2
Patients with SARS-COV 2 undergoing CT-V
|
CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predictive association between CT-V, PBM score and disease progression
Time Frame: 30 days
|
Disease progression will be characterized as requiring mechanical ventilator support, non-invasive positive pressure ventilation, high flow nasal cannula or mortality within 30 days.CT-V and PBM scores will be calculated at a voxel level from inhalation-exhalation CT scan.
Several CT-V pulmonary function metrics, including the volume of identified "cold spots" (areas with decreased ventilation and perfusion), total ventilation and perfusion and radiographic fibrosis score will be calculated to assess regional ventilation/perfusion and compared to disease progression.
The number of participants with correlation between these factors will be reported.
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Girish B Nair, MD, William Beaumont Hospitals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 24, 2020
Primary Completion (Actual)
May 14, 2021
Study Completion (Actual)
May 14, 2021
Study Registration Dates
First Submitted
March 23, 2020
First Submitted That Met QC Criteria
March 23, 2020
First Posted (Actual)
March 25, 2020
Study Record Updates
Last Update Posted (Actual)
January 5, 2022
Last Update Submitted That Met QC Criteria
December 14, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-087
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Acute Respiratory Syndrome
-
Assistance Publique - Hôpitaux de ParisCompletedSevere Acute Respiratory Syndrome Coronavirus 2 | Severe Acute Respiratory Distress SyndromeFrance
-
Oneness Biotech Co., Ltd.CompletedDisease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)United States
-
NeuroActiva, Inc.UnknownSevere Acute Respiratory Syndrome | Covid19 | Corona Virus Infection | Severe Acute Respiratory Syndrome (SARS) Pneumonia | Neurodegeneration | Neuroinflammatory Response | Severe Acute Respiratory Infection | Severe Acute Respiratory Syndrome of Upper Respiratory TractUnited States
-
Hôpital Universitaire SahloulCompleted
-
Wits Health Consortium (Pty) LtdFred Hutchinson Cancer Center; Janssen Vaccines & Prevention B.V.; National Institute... and other collaboratorsCompletedSARS (Severe Acute Respiratory Syndrome)South Africa
-
Laboratorios Silanes S.A. de C.V.CompletedSevere Acute Respiratory Syndrome Coronavirus 2Mexico
-
Throne Biotechnologies Inc.Not yet recruitingSevere Acute Respiratory Syndrome (SARS) Pneumonia
-
TakedaCompletedPrevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Japan
-
Massachusetts General HospitalXijing Hospital; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Niguarda...CompletedCoronavirus | SARS (Severe Acute Respiratory Syndrome)United States, Sweden
-
University of SaskatchewanGovernment of Canada; Vaccine Formulation Institute (VFI); Government of Saskatchewan and other collaboratorsCompletedSevere Acute Respiratory Syndrome Coronavirus 2Canada
Clinical Trials on CT-V
-
University Hospital, BrestRecruiting
-
UMC UtrechtRecruitingPulmonary Embolism | Ventilation Perfusion MismatchNetherlands
-
Assiut UniversityNot yet recruitingCTEPH Predictors
-
Indiana UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingAcute Kidney Injury | Pulmonary Embolism | Contrast-induced NephropathyUnited States
-
William Beaumont HospitalsTerminatedPulmonary Fibrosis | Lung Diseases, InterstitialUnited States
-
IlDong Pharmaceutical Co LtdCompleted
-
University Hospital, BrestNot yet recruiting
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)TerminatedAcute Lung Injury | Chronic Obstructive Pulmonary Disease (COPD)United States
-
Livzon Pharmaceutical Group Inc.Active, not recruiting